Biological E’s Corbevax has been approved for administration to children aged 5-12 years in India and Bharat Biotech’s Covaxin has been approved for restricted use in emergency situation in children aged 6-12 years.
The Drugs Controller General of India (DCGI) has given emergency use authorisation to Bharat Biotech’s Covaxin for children between the age group of 6-12.
The DCGI has also granted emergency use authorisation to Corbevax for children between the age of 5-12 years. The vaccine is currently being administered to those in the age group of 12-14.
The DCGI approval comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO), as cases spike in Indian schools.
The DCGI has directed the vaccine maker to submit the safety data with due analysis every 15 days for the first two months. Bharat Biotech has to submit the data monthly for up to 5 months, afterwards.
Currently, India is only administering Covid-19 vaccines to those above 12 years — Corbevax for 12-14 years and Covaxin for 15-18 years.
Covaxin was approved for 12 to 18 years on December 24, 2021. It’s currently being administered to those in the 15-18 age group.
